ReviewHuman vaccines & immunotherapeutics2018
Revaccination against hepatitis B in late teenagers who received vaccination during infancy: Yes or no?
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective.NPJ vaccines · 2025Article
- Seroprevalence Study of Anti-HBs Antibodies in the General Population of Vojvodina, Serbia.Medicina (Kaunas, Lithuania) · 2024Article
- Epidemiological and clinical profile of pediatric hepatitis B virus infections in Wuhan: a retrospective cohort study.BMC pediatrics · 2023Article
- Hepatitis B immunization status and risk factors of people aged 1 to 69 in Huangpu District, Shanghai, China.Frontiers in public health · 2023Article
- Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccinees.Human vaccines & immunotherapeutics · 2021Article
- Hepatitis B vaccine development and implementation.Human vaccines & immunotherapeutics · 2020Article
- Immune response to hepatitis B vaccination in pediatric patients with inflammatory bowel disease.Central-European journal of immunology · 2020Article
- Association between Body Mass Index and Hepatitis B antibody seropositivity in children.Korean journal of pediatrics · 2019Article
- Long-term persistency of hepatitis B immunity: an observational cross-sectional study on medical students and resident doctors.Journal of preventive medicine and hygiene · 2019Observational
- Comparison of hepatitis B viral loads and viral antigen levels in child-bearing age women with and without pregnancy.BMC pregnancy and childbirth · 2018Article
- From infancy and beyond… ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity.Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significance of vaccination against hepatitis B during infancy is recognized worldwide, however, whether booster or revaccination after a period of time following the primary vaccination is required remains controversial. Recently, cross-sectional epidemiological surveys found that HBsAg prevalence in subjects born after the implementation of mass vaccination was increased with age, which was attributed to waning of anti-HBs over time. However, comprehensive analysis of the closely related cross-sectional surveys showed that the age-specific increased HBsAg prevalence was more likely associated with the carry-over of the infection occurred in early life, likely due to imperfect coverage of hepatitis B vaccination at the beginning of its introduction. Latest studies showed that booster response could be observed in the majority of individuals vaccinated 30 years ago. Moreover, confirmed breakthrough HBV infection with severe consequences in successfully vaccinated individuals is extremely rare. Thus far no compelling evidence has been acquired to support booster vaccination in adolescence. The uncertainty regarding the duration of protection of hepatitis B vaccination, especially beyond 30 years after the primary vaccination, merits a systematically designed study to follow the same cohort of participants longitudinally, which differs from the cross-sectional studies reported previously, can hopefully offer more direct evidence to help us to determine whether revaccination of hepatitis B vaccine is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.